Loading clinical trials...
Loading clinical trials...
Phase 2 Trial of 5-Fluorouracil, Oxaliplatin and Liposomal Irinotecan and Immunotherapy (Plus Trastuzumab for HER2-positive Disease) During 1st Line Treatment of Advanced Esophageal and Gastric Adenocarcinoma
Conditions
Interventions
Nal-IRI
Oxaliplatin
+4 more
Locations
1
United States
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, United States
Start Date
July 13, 2020
Primary Completion Date
December 1, 2026
Completion Date
December 1, 2027
Last Updated
February 24, 2026
NCT06340711
NCT05745857
NCT06901531
NCT05733689
NCT04900818
NCT05677490
Lead Sponsor
University of Wisconsin, Madison
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions